Prostate Cancer - Results from #1020

A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia. April 24, 2024

The Critical Interplay of CAF Plasticity and Resistance in Prostate Cancer. April 24, 2024

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids. April 24, 2024

PGC-1α drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacity. April 24, 2024

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. April 24, 2024

Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer. April 23, 2024

Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition. April 23, 2024

The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression. April 23, 2024

A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers. April 23, 2024

Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways. April 23, 2024

Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the April 23, 2024

Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies. April 23, 2024

Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years. April 23, 2024

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. April 23, 2024

A Ten Year Experience of Men's Health Events in a Socioeconomically Diverse City in the United States - Lessons Learned. April 23, 2024

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency. April 23, 2024

p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer. April 22, 2024

Oncogenic ETS fusions promote DNA damage and proinflammatory responses via pericentromeric RNAs in extracellular vesicles. April 22, 2024

Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer. April 22, 2024

Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. April 22, 2024

Page 52 of 1436